The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors

New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The meeting is taking place both virtually and at the George R. Brown Convention Center in... […]"